1. Home
  2. MXL vs NUVB Comparison

MXL vs NUVB Comparison

Compare MXL & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MaxLinear Inc.

MXL

MaxLinear Inc.

HOLD

Current Price

$22.03

Market Cap

1.6B

Sector

Technology

ML Signal

HOLD

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$4.81

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MXL
NUVB
Founded
2003
2018
Country
United States
United States
Employees
N/A
298
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
2009
N/A

Fundamental Metrics

Financial Performance
Metric
MXL
NUVB
Price
$22.03
$4.81
Analyst Decision
Buy
Strong Buy
Analyst Count
5
8
Target Price
$19.80
$11.38
AVG Volume (30 Days)
930.5K
3.1M
Earning Date
04-23-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
46.08
N/A
EPS
N/A
N/A
Revenue
$478,596,000.00
N/A
Revenue This Year
$22.10
$205.55
Revenue Next Year
$10.70
$58.57
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.08
$1.57
52 Week High
$21.63
$9.75

Technical Indicators

Market Signals
Indicator
MXL
NUVB
Relative Strength Index (RSI) 73.61 55.66
Support Level $15.97 $4.06
Resistance Level N/A $5.55
Average True Range (ATR) 0.87 0.24
MACD 0.51 0.10
Stochastic Oscillator 100.00 89.27

Price Performance

Historical Comparison
MXL
NUVB

About MXL MaxLinear Inc.

MaxLinear Inc is a provider of radio frequency and mixed-signal integrated circuits for cable and satellite broadband communications, the connected home, and for data center, metro, and long-haul fiber networks. The company's radio frequency receiver products capture and process digital and analog broadband signals to be decoded for various applications. Its product options include both radio frequency receivers and radio frequency receiver systems-on-chips. The company's products enable the distribution and display of broadband video and data content in a wide range of electronic devices.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: